NIKKEI 225
26,739.03 +336.19 (+1.27%) HANG SENG
20,717.24 +596.56 (+2.96%) CRUDE OIL
110.35 +0.46 (+0.42%) GOLD FUTURES
1,845.10 +3.90 (+0.21%) DOW
31,261.90 +8.77 (+0.03%) BTC-GBP
24,267.11 +590.57 (+2.49%)
Novartis AG (0QLR.IL)
| Previous close | 86.78 |
| Open | 86.65 |
| Bid | 84.56 x N/A |
| Ask | 88.88 x N/A |
| Day's range | 86.21 - 87.12 |
| 52-week range | 72.84 - 89.28 |
| Volume | |
| Avg. volume | 2,025,018 |
| Market cap | 194B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 21.81 |
| EPS (TTM) | 3.98 |
| Earnings date | N/A |
| Forward dividend & yield | 3.10 (3.62%) |
| Ex-dividend date | 08 Mar 2022 |
| 1y target est | N/A |
- Globe Newswire
Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions
Positive opinion could expand the role of Cosentyx® (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EUSafety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indicationsSince its initial approval, Cosentyx has a proven sustained efficacy profile across several systemic inflammatory conditions and has treated more than 700,000 patients worldwide 1-11 Ba
- Zacks
Alnylam's (ALNY) Marketed Drugs Aid Growth Amid Competition
Alnylam's (ALNY) portfolio of approved drugs is witnessing strong uptake so far while its pipeline is progressing well. However, stiff competition in the target market remains a woe.
- Motley Fool
Should You Buy This High-Yielding Big Pharma Stock?
Novartis can provide investors with a market-crushing 3.8% dividend yield -- and that isn't all the stock has to offer.
